Intensity Therapeutics, Inc.

8 Wright Street
Suite 107
Westport
Connecticut
06880
United States

Tel: 203-682-2434
Fax: 203-664-1051

Website: http://www.intensitytherapeutics.com/

About Intensity Therapeutics, Inc.

Intensity Therapeutics is a biotechnology company whose mission is to greatly extend the lives of cancer patients. Late stage solid cancer consists of well-defined visible tumors and unseen micro-metastases either in the blood or body tissue. Cancer is thus both a regional and a systemic disease. To have an effective treatment against cancer one must destroy both the existing large observable tumors as well as the unseen micrometastases. Intensity Therapeutics was thus founded to develop a new approach to treat both the big and the small aspects of the disease - in situ vaccination. Using our DfuseRxSM platform, we create novel formulations of proven drugs. Our products have high diffusion and dispersion properties in tumors. When injected directly into a tumor or visible metastases these products are able to kill the tumors and create sites for an adaptive immune response. The observed adaptive immune response further increases the efficacy of our system to destroy or regress the tumor, eliminate secondary tumors and micrometastases as well. The Company demonstrated that complete regression (CR) of large tumors in mice is possible using the technology. Animals that had a CR became fully resistant to re-inoculation of the same cancer.
YEAR FOUNDED:
2012
LEADERSHIP:
CEO: Lewis H. Bender
Chief Medical Officer: Ian B. Walters, MD

24 articles with Intensity Therapeutics, Inc.

Intensity Therapeutics' INT230-6 Induces Immune Activation by Intratumoral Delivery as Reported in the Peer-Reviewed Journal OncoImmunology

7/17/2019

INT230-6 shows ability to regress tumors and initiate a T cell mediated systemic immune response against cancer
Intensity Therapeutics Announces Clinical Collaboration with Merck

6/25/2019

Phase 1/2 clinical trial to evaluate Intensity’s INT230-6 in combination with KEYTRUDA® (pembrolizumab) for multiple solid tumor types
Intensity Therapeutics Presents Positive Preliminary Phase 1/2 Results for Intratumoral Injection of INT230-6 at ASCO 2019

6/1/2019

Intensity Therapeutics, Inc. announced positive preliminary results from the company’s ongoing Phase 1/2 clinical trial of its lead product candidate, INT230-6, in a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Intensity Therapeutics to Present Data on Safety, Tumor Regression and Immune Activation of INT230-6 at ASCO 2019

5/16/2019

Intensity Therapeutics, Inc. announced that a poster highlighting the safety profile, tumor regression activity and immune activation of the company’s lead product candidate, INT230-6, will be presented at the American Society of Clinical Oncology Annual Meeting, taking place May 31 to June 4, 2019 in Chicago.
Intensity Therapeutics Raises $6.5 Million in Series B Financing

11/2/2018

Proceeds to enable advancement of lead product candidate INT230-6 into Phase 2 clinical development for solid tumors
Portage provides update on SalvaRx portfolio company, Intensity Therapeutics, Inc.

10/22/2018

Portage Biotech Inc. ("Portage" or the "Company") wishes to provide an update on a SalvaRx Limited portfolio company, Intensity Therapeutics, Inc. ("Intensity"). SalvaRx Limited holds an 8.5% equity interest in Intensity.
Intensity Therapeutics, Inc. Announces Presentation on INT230-6 Clinical Study at the 2018 ASCO Conference

5/31/2018

The 2018 American Society of Clinical Oncology (ASCO) Annual Meeting is taking place June 1-5 in Chicago.
Mark A. Goldberg, MD Joins Intensity Therapeutics, Inc. Board of Directors

5/17/2018

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immune-based drug products for direct intratumoral injection, today announced that Mark A. Goldberg, MD has been appointed to the Company's Board of Directors effective May 1, 2018.
Intensity Therapeutics, Inc. Reports Positive Safety Data from Ongoing IT-01 Phase 1/2 Trial

2/27/2018

Study Steering Committee approves opening cohorts for dosing to deep tumors and more frequent treatment into superficial tumors
Intensity Therapeutics, Inc. Issued New Patents For Technology Platform

6/15/2017
Intensity Therapeutics, Inc. Successfully Administers INT230-6 To First Patient In A Phase I/II Trial

5/30/2017
Intensity Therapeutics, Inc. Reports That INT230-6 Induces Protective T-Cell Immunity In Preclinical Models

4/4/2017
Intensity Therapeutics, Inc. Raises $10 Million To Fund Clinical Supplies Manufacturing And Phase I/II Trials Of INT230-6

6/28/2016
Intensity Therapeutics, Inc. Issued First U.S. Patent For Immune-based Cancer Therapeutic Agents

6/2/2016
Intensity Therapeutics, Inc. Reports That INT230-6’s Anti-Cancer Mechanism Is A Combination Of Cell Death With Immune System Activation

4/19/2016
Intensity Therapeutics, Inc. Selected To Present At BioCentury Future Leaders Conference

3/8/2016
Intensity Therapeutics, Inc. Reports Anti-Cancer Immunological Effect Generated By INT230-6

3/3/2016
Intensity Therapeutics, Inc. Reports Anti-Cancer Immunological Effect Generated By INT230-6

3/3/2016
Intensity Therapeutics, Inc. Preclinical Results Show Anti-Cancer Synergy Of INT230-6 With Anti-PD-1 Compounds

11/5/2015
Intensity Therapeutics, Inc. Forms Scientific Advisory Board Comprised Of World-Leading Oncologists And Scientists

10/22/2015